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Measurement of extended half-life recombinant factor IX products in 
clinical practice. 
Bowyer AE, Shepherd MF, Kitchen S, Maclean RM, Makris M 
Introduction/aim 
The introduction of extended half-life (EHL) recombinant Factor IX (rFIX) products for 
the treatment of haemophilia B (HB) has improved patient quality of life [1] however 
the complexities of accurately measuring product recovery has created uncertainty 
within haemostasis laboratories. 
Two EHL products; FIX albumin fusion protein, albutrepenonacog alfa, (rFIX FP, 
Idelvion, CSL Behring, King of Prussia, USA) and FIX Fc fusion, eftrenonacog alfa, 
(rFIX Fc, Alprolix, Bioverativ, Waltham, USA), have been in routine use in the UK 
since 2016.  Following on from field study data involving artificially spiked plasma, 
both manufacturers advise against the use of certain APTT reagents in the 
laboratory measurement of their product by the one-stage APTT based assay (OSA) 
[2, 3]. The recommended potency assignment for replacement FIX products is by 
one-stage clotting assay (OSA) [4].  The potency for Alprolix was assigned by OSA 
using Actin APTT reagent [5].  To the best of our knowledge, the APTT reagent used 
for assignment of Idelvion potency is not in the public domain, however Pathromtin 
SL has been used in previous clinical trials of Idelvion [2]. Reports in the literature 
assessed EHL product recovery in assays of FIX activity (FIX:C) using in vitro spiked 
plasma and again, WRWKHDXWKRUV¶NQRZOHGJHQRUHSRUWVRISURGXFWUHFRYHU\LQ
patients have been published. Findings based on spiked samples should be 
confirmed with post infusion samples from patients in case of in vivo modifications or 
interactions that could affect assay results. The aim of this study was to assess 
recovery of FIX by OSA and chromogenic substrate assay (CSA) in HB patients 
treated with Idelvion or Alprolix. 
Methods 
FIX:C was measured by OSA and CSA in eighteen samples from three HB patients 
on prophylactic treatment with Idelvion and twenty-two samples from five HB patients 
on prophylactic treatment with Alprolix.  OSA were performed with Actin, Actin FS 
(AFS), Actin FSL and Pathromtin SL (PSL) APTT reagents and FIX deficient plasma 
(all Siemens, Marburg, Germany) on a Sysmex CS5100i analyser and APTT SP, 
SynthASil and SynthAFax APTT reagents and FIX deficient plasma (all Werfen, 
Barcelona, Spain) on an ACL TOP analyser. Specific calibration curves were 
performed for each reagent using Siemens standard human plasma or Werfen 
HemosIL calibrator plasma.  Each sample was tested at 3 dilutions and results were 
obtained by double logarithmic plot then extrapolation of parallel line. CSA, at two 
sample dilutions, were performed on a Sysmex CS5100i with kits from Rossix 
(Mölndal, Sweden) and Hyphen Biomed (Neuville-sur-Oise, France) with calibration 
curves performed using Hyphen Biomed calibrator plasma. 
Percentage difference was calculated per sample by (a-b/b) x 100 where a was the 
FIX:C using alternative APTT reagents or CSA and b was the FIX:C using either 
Pathromtin SL in Idelvion samples or Actin in Alprolix samples.  
Results 
Idelvion 
The overall median OSA FIX:C for 18 samples from Idelvion-treated patients was 48 
IU/dL with PSL, with other OSA ranging from 28 IU/dL(AFS) to 63 IU/dL (SynthAFax) 
and using CSA was 82 IU/dL with Rossix and 66 IU/dL with Hyphen (see table 1). At 
high levels, FIX:C ranged from 46 IU/dL (AFS) to 137 IU/dL (Rossix CSA) in the 
same sample; PSL was 78 IU/dL. At trough levels, FIX:C varied from 4 IU/dL (both 
CSA) to 9 IU/dL (Actin) in the same sample; PSL was 6 IU/dL. Percentage 
differences were calculated using PSL as the target result.  For OSA the median 
percentage difference ranged from -3.5% with Actin to 42.5% with SynthAFax. For 
CSA the median percentage difference was 71.5% with Rossix and 41.1% with 
Hyphen (table 1 and figure 1). 
 
Alprolix 
The median OSA FIX:C for 22 samples from Alprolix-treated patients ranged from 33 
IU/dL with PSL to 53 IU/dL with Actin.  Median CSA was 49 IU/dL with Rossix and 34 
IU/dL with Hyphen (see table 1). At high levels, the largest FIX:C variation in a single 
samples was 65 IU/dl with APTT SP and 94 IU/dl with Actin. A single patient had a 
IX:C of below 10 IU/dL with Actin and the range of results was 3 IU/dl (Rossix CSA) 
to 8 IU/dl (Actin, APTT SP and Synthasil) in this sample.  Percentage differences 
were calculated using Actin as the target result. The median OSA percentage 
difference ranged from -22% with Synthasil to -27.4% with PSL. For CSA, the 
median percentage difference was -3.7%% with Rossix and -30.8% with Hyphen 
(table 1 and figure 1).  
 
Discussion/ Conclusions 
The laboratory monitoring of FIX products which have been modified by fusion to 
albumin or the Fc portion of IgG1 molecules or by linkage of polyethylene glycol, has 
become a challenging issue. The results of pharmaceutical company instigated field 
studies using plasma spiked with these EHL rFIX products have indicated that some 
commonly used APTT reagents would not be suitable for accurate measurement of 
these products [2, 3, 6]. A plethora of APTT reagents are in routine laboratory use 
worldwide and full details of the one-stage method used for potency assignment of 
the individual products are not always freely available.  
The use of Actin FS or CK Prest APTT reagents to monitor Idelvion was reported to 
underestimate the product recovery by approximately 50% in spiked plasma [3].  In 
this present study, medians of less than 10% difference from Pathromtin SL were 
observed with Actin, APTT SP and SynthASil in Idelvion-treated patients.  Median 
underestimation by greater than 35% was observed with AFS and Actin FSL and 
overestimation by greater than 40% was observed with SynthAFax and both CSA.  
These latter methods also may not be suitable for routine monitoring of Idelvion in 
vivo but more data is required to substantiate these findings.  A trend of increasing 
percentage difference with increasing FIX:C was observed with both CSA and 
Synthafax OSA.  Similar non-linear relationships between some modified FVIII and 
FIX molecules at measured at increasing plasma concentrations with certain 
reagents have been reported in spiked plasma [2, 7]  
Field studies that used plasma artificially spiked with Alprolix concluded that the 
product may be measured by OSA with APTT reagents comprising ellagic acid or 
silica activators.  The kaolin-based reagent, CK Prest, which underestimated the 
expected recovery by 20-40% depending upon the FIX:C activity, would not be 
acceptable for monitoring [2, 7].  
In HB patients treated with Alprolix, the target FIX:C was determined using OSA and 
Actin APTT reagent.  In our study, Rossix CSA demonstrated the best agreement 
with Actin FIX:C.  The remaining reagents demonstrated approximately 30% 
difference compared to Actin although this was extremely variable for each patient 
sample.  Alprolix samples with FIX:C below 15 IU/dL demonstrated much greater 
percentage difference of up to 63%, than those with higher activity.  All samples with 
Actin FIX:C of greater than 50 IU/dL demonstrated less than 36% difference with the 
remaining reagents.  A clear dose dependent trend of decreasing percentage 
difference at increasing FIX:C was observed with SynthAFax OSA and Hyphen 
Biomed CSA.  
 
Currently, there is no international consensus of the degree of variation between 
reagents or assay methods measuring the same parameter which could be expected 
to alter the clinical management of patients.  20-30% difference has been considered 
acceptable in several studies.[2, 8, 9].  At FIX:C below 10 IU/dL, the calculation of 
percentages can magnify small differences in activity which may not be clinically 
significant. Since FIX:C trough levels can be used to tailor patient dosing regimens, it 
is important that these can be accurately determined, however, field studies have 
reported significant variability at low FIX:C concentrations [2, 3, 6, 7]. The HB 
patients included in this study demonstrated up to two fold difference in FIX:C with 
some reagents, irrespective of rFIX concentrate, a disparity which may influence 
clinical decisions.  
Results in this ex vivo study confirm and extend in vitro spiking data for both Idelvion 
and Alprolix.  The activator present in the APTT reagents tested, either ellagic acid 
or silica-based, did not appear to consistently influence results for either EHL FIX 
product but other reagents should be tested locally before use. Each patient included 
in this present study had samples from more than one venepuncture and no patient-
specific trends were observed within the cohort.  Our data confirms that the accurate 
monitoring of patients on Idelvion or Alprolix is dependent upon the use of the 
appropriate assay.  It is therefore essential that laboratories and clinicians are aware 
of the characteristics of the specific FIX:C assays used in their centres and how 
these interact with different EHL products. Our data support the recommendation 
that laboratories should use an assay that has been validated for use with the 
specific extended half life concentrate being used. (10) 
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